Cargando…
Sexual dimorphism in atrophic effects of topical glucocorticoids is driven by differential regulation of atrophogene REDD1 in male and female skin
Topical glucocorticoids, well-known anti-inflammatory drugs, induce multiple adverse effects, including skin atrophy. The sex-specific effects of systemic glucocorticoids are known, but sexual dimorphism of therapeutic and side effects of topical steroids has not been studied. We report here that fe...
Autores principales: | Baida, Gleb, Agarwal, Shivani, Readhead, Ben, Dudley, Joel T., Budunova, Irina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6996908/ https://www.ncbi.nlm.nih.gov/pubmed/32064044 http://dx.doi.org/10.18632/oncotarget.27445 |
Ejemplares similares
-
REDD1 functions at the crossroads between the therapeutic and adverse effects of topical glucocorticoids
por: Baida, Gleb, et al.
Publicado: (2015) -
Selective Activator of the Glucocorticoid Receptor Compound A Dissociates Therapeutic and Atrophogenic Effects of Glucocorticoid Receptor Signaling in Skin
por: Klopot, Anna, et al.
Publicado: (2015) -
PI3K inhibitors protect against glucocorticoid-induced skin atrophy
por: Agarwal, Shivani, et al.
Publicado: (2019) -
Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy
por: Baida, Gleb, et al.
Publicado: (2018) -
Important role of kallikrein 6 for the development of keratinocyte proliferative resistance to topical glucocorticoids
por: Kishibe, Mari, et al.
Publicado: (2016)